左西孟旦对脓毒性休克患者细胞代谢改变的影响:一项随机对照先导研究
该研究为前瞻性、双盲、对照、临床先导试验,在 multidisciplinary 重症监护病房进行,纳入20例脓毒性休克患者。在达到正常血容量和平均动脉压至少65 mmHg后,随机接受左西孟旦0.2 μg/kg/min(n=10)或多巴酚丁胺5 μg/kg/min作为活性对照(n=10)。通过肌肉微透析测定骨骼肌细胞外液中乳酸、丙酮酸、葡萄糖和甘油的浓度,并在基线及随机化后72小时内每6小时测量一次,同时获取右心导管数据。结果显示,与多巴酚丁胺相比,左西孟旦增加间质丙酮酸浓度和乳酸清除率(55 vs. 10),研究结束时左西孟旦组乳酸/丙酮酸比值更低(P<0.05)。作者结论认为,尽管样本量小,初步结果提示左西孟旦可能改善脓毒性休克患者的细胞代谢改变。
要点
- 在20例脓毒性休克患者中,左西孟旦0.2 μg/kg/min组间质丙酮酸浓度高于多巴酚丁胺5 μg/kg/min组(153.3 ± 73 和 187.2 ± 13.5 vs. 210.7 ± 76.2 和 161 ± 64.6;P<0.05)。
- 左西孟旦组乳酸清除率为55,多巴酚丁胺组为10。
- 研究结束时左西孟旦组乳酸/丙酮酸比值低于多巴酚丁胺组(37.7 ± 18.9 和 29.3 ± 12.7 vs. 10.9 ± 4.5 和 31.4 ± 13.2;P<0.05)。
- 作者认为,尽管样本量小,初步结果提示左西孟旦可能改善脓毒性休克患者的细胞代谢改变。
适用人群与场景
- 脓毒性休克患者,在达到正常血容量和平均动脉压至少65 mmHg后纳入。
处置流程与药物剂量
- 达到正常血容量和平均动脉压至少65 mmHg后,随机给予左西孟旦0.2 μg/kg/min(n=10)或多巴酚丁胺5 μg/kg/min作为活性对照(n=10)。
- 通过肌肉微透析测定间质乳酸、丙酮酸、葡萄糖和甘油浓度,基线及随机化后72小时内每6小时测量一次,同时获取右心导管数据。
研究设计与关键结果
- 研究设计为前瞻性、双盲、对照、临床先导试验,在 multidisciplinary 重症监护病房进行,共纳入20例脓毒性休克患者,随机分为左西孟旦组(n=10)和多巴酚丁胺组(n=10)。
- 与多巴酚丁胺相比,左西孟旦增加间质丙酮酸浓度(153.3 ± 73 和 187.2 ± 13.5 vs. 210.7 ± 76.2 和 161 ± 64.6;P<0.05),乳酸清除率为55 vs. 10。
- 研究结束时左西孟旦组乳酸/丙酮酸比值低于多巴酚丁胺组(37.7 ± 18.9 和 29.3 ± 12.7 vs. 10.9 ± 4.5 和 31.4 ± 13.2;P<0.05)。
- 试验注册号:NCT02963454。
证据类型、等级与局限
- 证据类型:前瞻性、双盲、对照、临床先导试验。
- 局限:作者自述样本量小(20例),结果为初步结果。
对床旁实践的改变
- 作者认为,左西孟旦可能改善脓毒性休克患者的细胞代谢改变,但该结论来自小样本先导研究,尚属初步。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
INTRODUCTION: Mitochondrial dysfunction and consequent cellular energetic failure play a key role in the development of sepsis-related organs failure. Evidence suggests that the pleiotropic effects of levosimendan may positively affect cellular metabolism during septic shock.
OBJECTIVES: To investigate changes in the concentration of glucose, lactate, pyruvate, and glycerol in the extracellular fluid of the skeletal muscle following levosimendan administration in patients with septic shock.
METHODS: The study was designed as a prospective, double-blind, controlled, clinical pilot trial and performed in a multidisciplinary intensive care unit. After achieving normovolemia and a mean arterial pressure of at least 65 mm Hg, 20 septic shock patients were randomized to receive either levosimendan 0.2 μg/kg/min (n = 10), or dobutamine 5 μg/kg/min as active comparator (n = 10). Interstitial tissue concentrations of lactate, pyruvate, glucose, and glycerol were obtained by using muscle microdialysis. All measurements, including data from right heart catheterization, were obtained at baseline and every 6 h for the following 72 h after randomization.The trial is registered with Clinicaltrials.gov, number NCT02963454.
RESULTS: Compared with dobutamine, levosimendan increased interstitial tissue pyruvate concentration (153.3 ± 73 and 187. 2 ± 13.5 vs. 210.7 ± 76.2 and 161 ± 64.6; P < 0.05), and lactate clearance (55 vs. 10). Lactate/pyruvate ratio was lower in the levosimendan group at the end of study period (37. 7 ± 18.9 and 29.3 ± 12.7 vs. 10.9 ± 4.5 and 31.4 ± 13. 2; P < 0.05).
CONCLUSION: Although we investigated a small number of patients, our preliminary results suggest that levosimendan may improve cellular metabolic alterations in patients with septic shock.
参考来源
- Hajjej Z, Meddeb B, Sellami W, et al. Effects of Levosimendan on Cellular Metabolic Alterations in Patients With Septic Shock: A Randomized Controlled Pilot Study. Shock. 2017. PMID: 28234790. doi:10.1097/SHK.0000000000000851
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。